Flying The Web For News.
  • Happy Holidays
    Happy Holidays
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: RYBREVANT®▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer

Details
Category: Globe NewsWire News Distribution Service

New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy1 Results from an interim analysis featured in late-breaker oral presentation at WCLC1


Posted: 2024-09-08 18:30:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | rybrevant®▼ | amivantamab | lazertinib


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: RYBREVANT®▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer - Newscast

FDA dents J&J's blockbuster hopes for Rybrevant

Mon, 23 Dec 2024 16:00:00 GMT The US regulator has turned down J&J's marketing application for a subcutaneous (SC) formulation of EGFRxMET bispecific antibody Rybrevant (amivantamab) – used to treat non-small cell lung ...

J&J's Rybrevant okay challenges Tagrisso in first-line NSCLC

Sun, 22 Dec 2024 16:01:00 GMT The FDA has approved EGFRxMET bispecific antibody Rybrevant (amivantamab) with third-generation EGFR tyrosine kinase inhibitor Lazcluze (lazertinib) for first-line use in locally advanced and ...

FDA Issues Complete Response to Johnson & Johnson's Application for Subcutaneous Rybrevant

Thu, 19 Dec 2024 12:24:00 GMT The agency's decision not to approve this formulation was based on issues identified during a pre-approval inspection at a manufacturing facility, the firm said.

FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC

Wed, 18 Dec 2024 12:15:00 GMT The FDA issued a complete response letter for the BLA submission of subcutaneous amivantamab for EGFR-mutated NSCLC, citing manufacturing inspection issues, but confirming no need for additional ...

FDA Rejects Subcutaneous Amivantamab for NSCLC Over Manufacturing Concerns

Tue, 17 Dec 2024 14:05:00 GMT Subcutaneous amivantamab joins a growing list of drugs receiving complete response letters due to manufacturing facility issues.


Blow Us A Whistle